Abstract:Chemotherapeutic agents have been widely used for cancer treatment in clinics. Aside from their direct cytotoxicity to cancer cells, some of them could activate the immune system of the host, contributing to the enhanced antitumor activity. Here, the reactive oxygen species (ROS)-responsive hydrogel, covalently cross-linked by phenylboronic acid-modified 7-ethyl-10-hydroxycamptothecin (SN38-SA–BA) with poly(vinyl alcohol) (PVA), is fabricated for topical delivery of anti-programmed cell death protein ligand 1 antibodies (aPDL1). In the presence of endogenous ROS, SN38-SA–BA will be oxidized and hydrolyzed, leading to the degradation of hydrogel and the release of initial free SN38 and encapsulated aPDL1. It is demonstrated that SN38 could elicit specific immune responses by triggering immunogenic cell death (ICD) of cancer cells, a distinct cell death pathway featured with the release of immunostimulatory damage-associated molecular patterns (DAMPs). Meanwhile, the released aPDL1 could bind to programmed cell death protein ligand 1 (PDL1) expressed on cancer cells to augment antitumor T cell responses. Thus, the ROS-responsive prodrug hydrogel loaded with aPDL1 could induce effective innate and adaptive antitumor immune responses after local injection, significantly inhibiting or even eliminating those tumors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c13943?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c13943</a>.Synthesis route of SN38-SA–BA (Scheme S1); gelation of different proportions among PVA, SN38-SA-BA, and PEG800 (Table S1); in situ 1H NMR spectra of SN38-SA-BA (BP) (Figure S1); fabrication of PVA-SN38 hydrogel (Figure S2); immune responses induced by PVA-SN38 hydrogel in vivo (Figure S3); percentage of CD8+ T cells and CD4+ T cells (Figure S4); biocompatibility of PVA-SN38 hydrogel in vivo (Figure S5); 1H and 13C NMR spectra of synthesized compounds (Figures S6–S14); and electrospray ionization high-resolution mass spectra (Figures S15–S18) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c13943/suppl_file/am0c13943_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy

Injectable Anti-inflammatory Nanofiber Hydrogel to Achieve Systemic Immunotherapy Post Local Administration

Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade

In situ forming an injectable hyaluronic acid hydrogel for drug delivery and synergistic tumor therapy

Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy

Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy

An Adhesive Immune‐Stimulating Multifunctional Hydrogel for Potent Tumor Chemoimmunotherapy and Postoperative Wound Healing Promotion

In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy

ROS-responsive thermosensitive polypeptide hydrogels for localized drug delivery and improved tumor chemoimmunotherapy

Multifunctional drug-loaded micelles encapsulated in thermo-sensitive hydrogel for in vivo local cancer treatment: Synergistic effects of anti-vascular and immuno-chemotherapy

Entrapping multifunctional dendritic nanoparticles into a hydrogel for local therapeutic delivery and synergetic immunochemotherapy

An injectable hydrogel based on Bi2Se3 nanosheets and hyaluronic acid for chemo-photothermal synergistic therapy

Intrinsic PD‐L1 Degradation Induced by a Novel Self‐Assembling Hexapeptide for Enhanced Cancer Immunotherapy

A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy

Injectable and Natural Humic Acid/Agarose Hybrid Hydrogel for Localized Light-Driven Photothermal Ablation and Chemotherapy of Cancer.

Injectable micellar supramolecular hydrogel for delivery of hydrophobic anticancer drugs

In situ formed reactive oxygen species-responsive dipyridamole prodrug hydrogel: Spatiotemporal drug delivery for chemoimmunotherapy

Hybrid Polydimethylsiloxane (PDMS) Incorporated Thermogelling System for Effective Liver Cancer Treatment

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRP alpha signal

Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy

Injectable Thermosensitive Polypeptide-Based CDDP-Complexed Hydrogel for Improving Localized Antitumor Efficacy.